AR053579A1 - Tratamiento de la enfermedad inflamatoria intestinal (eii) - Google Patents

Tratamiento de la enfermedad inflamatoria intestinal (eii)

Info

Publication number
AR053579A1
AR053579A1 ARP060101467A ARP060101467A AR053579A1 AR 053579 A1 AR053579 A1 AR 053579A1 AR P060101467 A ARP060101467 A AR P060101467A AR P060101467 A ARP060101467 A AR P060101467A AR 053579 A1 AR053579 A1 AR 053579A1
Authority
AR
Argentina
Prior art keywords
ibd
treatment
inflammatory disease
intestinal inflammatory
antibody
Prior art date
Application number
ARP060101467A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR053579A1 publication Critical patent/AR053579A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060101467A 2005-04-15 2006-04-12 Tratamiento de la enfermedad inflamatoria intestinal (eii) AR053579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67190205P 2005-04-15 2005-04-15

Publications (1)

Publication Number Publication Date
AR053579A1 true AR053579A1 (es) 2007-05-09

Family

ID=36685736

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101467A AR053579A1 (es) 2005-04-15 2006-04-12 Tratamiento de la enfermedad inflamatoria intestinal (eii)

Country Status (16)

Country Link
US (1) US20060233797A1 (enExample)
EP (1) EP1871414A1 (enExample)
JP (1) JP2008536855A (enExample)
KR (1) KR20070122543A (enExample)
CN (1) CN101184507A (enExample)
AR (1) AR053579A1 (enExample)
AU (1) AU2006236816A1 (enExample)
BR (1) BRPI0612321A2 (enExample)
CA (1) CA2605020A1 (enExample)
IL (1) IL186151A0 (enExample)
MX (1) MX2007012667A (enExample)
NO (1) NO20075845L (enExample)
RU (1) RU2007142188A (enExample)
TW (1) TW200714291A (enExample)
WO (1) WO2006113308A1 (enExample)
ZA (1) ZA200708850B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
EP2178916B1 (en) 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
EP2262509A4 (en) * 2008-03-07 2012-02-22 Lawrence Bernstein GALLIUM COMPOUNDS AND METHOD OF USE FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
US8206940B2 (en) * 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
TWI598363B (zh) 2011-04-21 2017-09-11 必治妥美雅史谷比公司 拮抗ｃｄ４０之抗體多肽
WO2013090989A1 (en) * 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN103149371B (zh) * 2013-02-26 2015-12-23 哈药慈航制药股份有限公司 生物标记物在制备预测5-氨基水杨酸治疗溃疡性结肠炎的反馈响应药物中的应用
SI3054996T1 (sl) 2013-10-07 2023-11-30 Igl Pharma, Inc. Postopek za pripravo terapevtskih sredstev za kosti visoke čistote
US10435475B2 (en) * 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PT3221359T (pt) 2014-11-17 2020-06-23 Regeneron Pharma Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
EP3548035A4 (en) * 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
KR20200003821A (ko) * 2017-04-07 2020-01-10 세컨드 게놈, 아이엔씨. 상피 장벽 기능 장애 치료용 단백질
WO2019018440A1 (en) 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
EP3737699A1 (en) 2018-01-12 2020-11-18 Amgen Inc. Pac1 antibodies and uses thereof
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
SG11202105345TA (en) 2018-11-21 2021-06-29 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
US20220091135A1 (en) * 2019-01-04 2022-03-24 Kyoto University Test method for ulcerative colitis and primary sclerosing cholangitis
CA3159053A1 (en) * 2019-12-06 2021-06-10 Sui Yi Kwok Method of treating inflammatory bowel disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69939939D1 (de) * 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
TR200101302T2 (tr) * 1998-11-09 2001-10-22 Idec Pharmaceuticals Corporation BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
KR20020020730A (ko) * 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
KR20020072277A (ko) * 1999-11-08 2002-09-14 아이덱 파마슈티칼즈 코포레이션 항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001072333A1 (en) * 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DE60139689D1 (de) * 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
EP2359849A1 (en) * 2001-04-02 2011-08-24 Genentech, Inc. Combination therapy
DE60233744D1 (de) * 2001-09-20 2009-10-29 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
NZ532526A (en) * 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
PT1558648E (pt) * 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
AR042485A1 (es) * 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
MXPA05010778A (es) * 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005017529A1 (en) * 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti cd20 antibodies and uses therefor
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JP2007504138A (ja) * 2003-08-29 2007-03-01 ジェネンテック・インコーポレーテッド 眼疾患の治療法
EP1696955A2 (en) * 2003-12-19 2006-09-06 Genentech, Inc. Detection of cd20 in therapy of autoimmune diseases
CN1980697A (zh) * 2004-05-05 2007-06-13 健泰科生物技术公司 通过使用抗cd20抗体预防自身免疫病

Also Published As

Publication number Publication date
MX2007012667A (es) 2007-12-13
EP1871414A1 (en) 2008-01-02
IL186151A0 (en) 2008-01-20
CA2605020A1 (en) 2006-10-26
BRPI0612321A2 (pt) 2010-11-03
NO20075845L (no) 2008-01-14
TW200714291A (en) 2007-04-16
US20060233797A1 (en) 2006-10-19
RU2007142188A (ru) 2009-05-20
JP2008536855A (ja) 2008-09-11
CN101184507A (zh) 2008-05-21
KR20070122543A (ko) 2007-12-31
WO2006113308A1 (en) 2006-10-26
ZA200708850B (en) 2009-03-25
AU2006236816A1 (en) 2006-10-26
WO2006113308A8 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AR053579A1 (es) Tratamiento de la enfermedad inflamatoria intestinal (eii)
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
EP2216344A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
UY33144A (es) Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana
MX342894B (es) Dosis de inmunoconjugados de anticuerpos y sn-38 para eficacia mejorada y toxicidad reducida.
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
Yakan et al. A rare cause of acute abdomen: small bowel obstruction due to phytobezoar
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
EP3788167A4 (en) METHODS OF DIAGNOSIS AND TREATMENT OF PATIENTS WITH CUTANEOUS SKATOPHONE CARCINOMA
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
Gholizadeh et al. Effects of self-management program and telephone follow up on medical adherence in patients with ischemic heart disease
BR112022017110A2 (pt) Composições e uso das mesmas
Wójcik et al. FRI0223 subphenotypes of ANCA associated vasculitis identified by latent class analysis
Peixoto First report of gouty arthritis in a patient with gout: case report
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof
Berruti Interferon-α-2b
WO2024239006A8 (en) Anti-tl1a antibody therapeutic methods
Rapoport et al. Durable Remissions Associated with anti-CTLA-4 and anti-PD1 Checkpoint Inhibitors in a Single Center.
Kilic Scleroderma: case report
AR120024A1 (es) ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO

Legal Events

Date Code Title Description
FA Abandonment or withdrawal